The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
This page is a live source preview, not a published PeDeDe article. A full PeDeDe story is only created after source verification, duplicate checking, research notes, original writing, and editorial review.